Clinical trial · Interventional
Detection of Circulating Biomarkers of Immunogenic Cell Death
Detection of Circulating Biomarkers of Immunogenic Cell Death After Radiotherapy and Chemotherapy: An Exploratory Study
NCT02921854CI-TRIAL-00040181ICDcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this exploratory study, the investigators will investigate if markers (molecular and immunological) of ICD or anti-tumor immunity (exosomal or molecular) can be detected in the serum of patients after high-dose radiotherapy alone or concurrent cisplatin-doublet therapy and radiotherapy. For each patient: withdraw blood at three times during treatment for analysis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood withdrawal | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- All included patients
- description
- 3 times Blood withdrawal for each patient (25ml each)
- interventionNames
- Other: Blood withdrawal
Primary outcomes (2)
- measure
- Changes of relative protein expression / derived exosomes, linked to ICD
- timeFrame
- 5 weeks (during radiotherapy)
- measure
- Changes of lipid profile for plasma / plasma, linked to ICD
- timeFrame
- 5 weeks (during radiotherapy)
Secondary outcomes (1)
- measure
- Changes of relative protein expression, linked to Th1/Th2 subsets
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male or female, aged 18 years or above. * Diagnosed with non-small cell lung cancer * Scheduled to receive one of the following two therapeutic strategies: * Concurrent cisplatin-doublet chemotherapy and radiotherapy (minimal dose of 60 Gy in fractionated non-ablative doses) in patients with stage III NSCLC * SBRT for stage I NSCLC: 54Gy in 3 fractions, 48 Gy in 4 fractions or 60 Gy in 8 or 5 fractions * Is able and willing to comply with all trial requirements. Exclusion Criteria: 1. Chronic use of corticosteroids, except when used as anti-emetics for chemotherapy or inhalers 2. NSAIDs taken until 5 days before radiotherapy or during radiation (low dose Aspirin at a maximum of 160 mg/day, is allowed) 3. Active auto-immune diseases 4. Immunosuppressive medication
References
Publications (0)
Data not yet available
No reference posted for this study.